Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis COVID-19
Status:
Recruiting
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
Study population: Patients with fibrotic lung sequelae after recovery from acute phase of
severe COVID19 pneumonia Objectives: To evaluate the effect of pirfenidone administered for
24 weeks in patients who have pulmonary fibrotic changes after suffering severe COVID19
pneumonia, analysed by
- % change in forced vital capacity (FVC)
- % fibrosis in high resolution computed tomography (HRCT) of the lung